Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.45 |
| ▸ | CNR1 | P21554 | 7/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31368095 | 0.89 | CNR2 (0.47) | CNR2CNR1MAPTTP53MAPK1 | |
| SCHEMBL31368123 | 0.84 | CNR2 (0.49) | CNR2CNR1MAPTMAPK1HTT | |
| SCHEMBL31368153 | 0.82 | CNR2 (0.47) | CNR2CNR1MAPTTP53MAPK1 | |
| SCHEMBL31368048 | 0.81 | CNR2 (0.46) | CNR2CNR1MAPTTP53MAPK1 | |
| SCHEMBL31368125 | 0.77 | CNR2 (0.48) | CNR2CNR1MAPTTP53MAPK1 | |
| SCHEMBL31368056 | 0.74 | CNR2 (0.52) | CNR2CNR1MAPTTP53MAPK1 | |
| SCHEMBL31368042 | 0.73 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL31368076 | 0.71 | CNR2 (0.48) | CNR2CNR1MAPTTP53MAPK1 | |
| SCHEMBL31368046 | 0.70 | CNR2 (0.47) | CNR2CNR1MAPTTP53MAPK1 | |
| SCHEMBL24380739 | 0.69 | CNR1 (0.48) | CNR2CNR1MAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2025037229-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS AG (CH) | 2025-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | MAPK1, MAP3K1, MAPK6 | CNR2 2020/4885CNR1 1719/4885TACR1 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.